Indication
Agitation, Psychomotor
9 clinical trials
11 products
1 drug
Clinical trial
Characterization of Tachyphylaxis, Tolerance, and Withdrawal After Discontinuation of Igalmi in Frequently Agitated Schizophrenic or Bipolar Patients After 7 Days of PRN TreatmentStatus: Recruiting, Estimated PCD: 2024-04-01
Product
IgalmiClinical trial
A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's TypeStatus: Completed, Estimated PCD: 2020-04-17
Product
BupropionProduct
AXS-05Product
PlaceboProduct
DexmedetomidineClinical trial
A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine Efficacy and Safety of BXCL501 In Agitation Associated With Bipolar DisorderStatus: Completed, Estimated PCD: 2020-05-21
Product
BXCL501Product
Matching PlaceboClinical trial
A Double-blind, Placebo-controlled, Randomized Withdrawal Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's TypeStatus: Completed, Estimated PCD: 2022-11-21
Clinical trial
Efficacy And Safety of BXCL501 Evaluated For At-Home Use In A Multisite Double-Blind Placebo-Controlled Trial For Agitation Associated With Schizophrenia And Bipolar DisorderStatus: Active (not recruiting), Estimated PCD: 2025-03-30
Clinical trial
A Phase Ib/II, Multicenter, Randomized, Double Blind, Placebo Controlled, Ascending Dose Finding, Efficacy, Pharmacokinetic and Safety Study of BXCL501 In Agitation Associated With DementiaStatus: Completed, Estimated PCD: 2022-01-24
Product
Sublingual PlaceboClinical trial
Open-Label Trial of a Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's DementiaStatus: Recruiting, Estimated PCD: 2024-09-15
Clinical trial
The Effect of Intraoperative Magnesium Sulfate Infusion on the Occurrence of Emergence Agitation After Pediatric Ophthalmic SurgeryStatus: Completed, Estimated PCD: 2018-12-19
Product
Magnesium SulfateDrug
VarlilumabClinical trial
Single-site, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Dronabinol for the Treatment of Agitation in Outpatient With DementiaStatus: Withdrawn, Estimated PCD: 2025-11-01
Product
Dronabinol